What is the recommended management of hepatitis C infection during pregnancy, including testing, treatment timing, delivery method, and breastfeeding guidance?

Hepatitis C Management in Pregnancy

All pregnant patients should be screened for hepatitis C virus with anti-HCV antibody testing during every pregnancy, and direct-acting antiviral therapy should only be initiated within clinical trials during pregnancy, with treatment deferred to the postpartum period in most cases. 1

Screening Recommendations

Universal Screening Protocol

• Screen all pregnant patients for HCV by testing for anti-HCV antibodies at the first prenatal visit, regardless of risk factors or prior testing. 1, 2 This universal screening approach is endorsed by the Society for Maternal-Fetal Medicine (SMFM), CDC, and USPSTF and has been shown to be cost-effective at prevalence rates as low as 0.03%. 1, 3

• If anti-HCV antibody is positive, confirm active infection with HCV RNA testing (nucleic acid test). 1

• Screen for intrahepatic cholestasis of pregnancy (ICP) in HCV-positive patients, as HCV infection increases ICP risk significantly (odds ratio 5.76-20.40). 1, 4, 2

Additional Testing for HCV-Positive Patients

• Screen for co-infections including HIV, syphilis, gonorrhea, chlamydia, and hepatitis B virus if not previously performed. 1, 2

• Vaccinate against hepatitis A and B viruses if the patient lacks immunity. 1, 2

Antepartum Management

Antiviral Treatment During Pregnancy

Direct-acting antiviral (DAA) regimens should only be initiated during pregnancy in the setting of a clinical trial. 1 The EASL guidelines similarly state that HCV treatment during pregnancy is not recommended in the absence of safety and efficacy data. 5

• For patients who become pregnant while taking DAAs, counsel them in a shared decision-making framework about risks and benefits of continuation versus discontinuation. 1 Treatment can be considered on a case-by-case basis after thorough discussion with hepatology and obstetric services. 5

• While early phase I studies of sofosbuvir/ledipasvir in 9 pregnant women showed all achieved sustained virological response with low adverse events, and ongoing trials are evaluating sofosbuvir/velpatasvir, these remain investigational. 5, 4, 5

Fetal Monitoring

• Third-trimester assessment of fetal growth may be performed, but routine antenatal testing is not indicated based on HCV diagnosis alone. 1, 2

• HCV infection is associated with increased risk of preterm birth (odds ratio 1.62), fetal growth restriction, low birthweight, and intrahepatic cholestasis of pregnancy. 4

Prenatal Diagnostic Testing

• If amniocentesis or chorionic villus sampling is requested, counsel patients that data regarding vertical transmission risk are reassuring but limited. 1 Amniocentesis is preferred over chorionic villus sampling given lack of data on the latter. 6

Intrapartum Management

Mode of Delivery

Cesarean delivery should not be performed solely for the indication of HCV infection. 1 Studies show no significant difference in vertical transmission rates between vaginal delivery and cesarean section. 3

Labor Management Precautions

• Avoid internal fetal monitors and early artificial rupture of membranes unless clinically necessary (i.e., when unable to trace fetal heart rate with external monitors and the alternative is cesarean delivery). 1, 2 These interventions may theoretically increase vertical transmission risk through increased blood exposure, though definitive evidence is lacking. 4

• Avoid prolonged rupture of membranes and episiotomy when managing labor in HCV-positive patients. 6

Postpartum Management

Breastfeeding Guidance

HCV status should not alter standard breastfeeding counseling and recommendations unless nipples are cracked or bleeding. 1 Available data show breastfeeding does not increase mother-to-child transmission risk. 5, 3

• In cases of bleeding or cracked nipples, consideration should be given to temporarily stopping breastfeeding due to potential HCV transmission from blood exposure, and specialist input should be provided. 5

Postpartum Treatment

• Defer DAA treatment to the postpartum period after cessation of breastfeeding for women diagnosed during pregnancy. 1 This represents the optimal timing for maternal cure while avoiding potential fetal/neonatal exposure to medications with limited safety data. 4

• Establish linkage to hepatology or infectious disease care for postpartum treatment initiation. Active patient navigation and colocation of services improve treatment uptake rates. 7

Infant Management

Vertical Transmission Risk

• The overall risk of mother-to-infant transmission is approximately 5-6%. 1, 6, 8 Higher maternal HCV viral loads (≥6 log IU/mL) are associated with increased transmission risk. 3

• HIV/HCV coinfection increases vertical transmission risk, particularly at lower HCV viral loads. 3

Infant Testing Protocol

• Test infants born to HCV-positive mothers with HCV RNA (nucleic acid test) at 2-6 months of age for early identification of perinatal infection. 9 This represents updated CDC guidance from 2023, replacing the previous recommendation for anti-HCV antibody testing at 18 months. 9

• If HCV antibody testing is performed at 18 months and positive, confirm with HCV RNA testing. 4

Common Pitfalls and Caveats

• Do not skip HCV screening based on perceived low risk or prior negative testing—universal screening is recommended for every pregnancy. 1, 2

• Do not initiate DAA therapy outside of clinical trials during pregnancy, even though treatment is highly effective and well-tolerated in non-pregnant populations. The lack of large-scale safety data in pregnancy necessitates caution. 1, 5, 1, 5

• Do not discourage breastfeeding in HCV-positive mothers with intact nipples—this represents a Grade 1A recommendation with strong evidence showing no increased transmission risk. 1

• Ensure accurate and timely communication of maternal HCV status to pediatric providers to facilitate appropriate infant testing and follow-up. 2